Provided by Tiger Fintech (Singapore) Pte. Ltd.

iTeos Therapeutics

10.17
+0.19001.90%
Post-market: 10.170.00000.00%16:44 EDT
Volume:1.11M
Turnover:11.21M
Market Cap:389.24M
PE:-3.29
High:10.19
Open:10.00
Low:9.96
Close:9.98
Loading ...
Jun 10, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 10, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 06, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 06, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 05, 2025

Major Issues Report

Form 8-K - Current report
Jun 05, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 05, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 04, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 04, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 28, 2025

Major Issues Report

Form 8-K - Current report
May 13, 2025

Major Issues Report

Form 8-K - Current report
Apr 29, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mar 05, 2025

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Mar 05, 2025

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Jan 13, 2025

Major Issues Report

Form 8-K - Current report
Nov 21, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Nov 18, 2024

Beneficial Ownership Change

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Nov 18, 2024

Beneficial Ownership Change

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Nov 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Nov 12, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]